Pay in 4 interest-free payments of $5.43 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
UK considerations NHS and MHRA guidance The UK health authorities have clear positions on weight loss treatments: The NHS offers GLP-1 medications through specialist weight management services for eligible patients MHRA has approved Wegovy, Saxenda, and Mounjaro based on comprehensive safety and efficacy data No GLP-1 patch products have received MHRA approval as weight loss treatments The MHRA has issued warnings about misleading claims in weight loss supplements Cost and access in the UK The financial aspect is a significant consideration for many: NHS provision : Limited availability through specialist weight management services with strict eligibility criteria Private prescriptions : 150-300 monthly, depending on medication and provider Commercial patches : 12-70 monthly, depending on brand and quantity While patches appear less expensive, they lack evidence of effectiveness, making them poor value regardless of price
The Phase 2 trial results Published in the New England Journal of Medicine, the Phase 2 trial showed that participants receiving the highest dose of retatrutide (12mg weekly) achieved a mean weight reduction of 24.2% at 48 weeks
Your healthcare team can develop a personalised management plan that balances maternal metabolic health with infant safety throughout the lactation period and beyond
GLP-1s further contribute by reducing the burden of excess weight, making movement easier and more enjoyable
they also did not exhibit heart abnormalities
US$ 22.78
US$ 25.18
US$ 29.00
US$ 22.61
